NKTX
Nkarta, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.92
+4.66%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
Market Cap
$209.14M
MomentumView details →
1D Return
+4.66%
YTD Return
+53.41%
RSI (14)
62.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
Market Cap
$209.14M
RSI (14)
62.4
MomentumView details →
1D Return
+4.66%
YTD Return
+53.41%
SummaryUpdated Jun 1, 2026
Nkarta, Inc. (NASDAQ:NKTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in South San Francisco, California. The company went public in July 2020 and focuses on developing innovative cell therapies for cancer treatment using engineered natural killer (NK) cells. Nkarta represents part of the emerging field of cellular immunotherapy, where immune cells are modified to better recognize and attack cancer cells.
Similar companies
Latest newsMore news →